Anatomical Laser Microdissection of the Ileum Reveals mtDNA Depletion Recovery in A Mitochondrial Neuro-Gastrointestinal Encephalomyopathy (MNGIE) Patient Receiving Liver Transplant.
MNGIE
gastrointestinal degeneration
microanatomical dissection
mitochondrial disorders
mtDNA depletion
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Aug 2022
08 Aug 2022
Historique:
received:
18
07
2022
revised:
03
08
2022
accepted:
04
08
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE) is a rare genetic disorder characterized by thymidine phosphorylase (TP) enzyme defect. The absence of TP activity induces the imbalance of mitochondrial nucleotide pool, leading to impaired mitochondrial DNA (mtDNA) replication and depletion. Since mtDNA is required to ensure oxidative phosphorylation, metabolically active tissues may not achieve sufficient energy production. The only effective life-saving approach in MNGIE has been the permanent replacement of TP via allogeneic hematopoietic stem cell or liver transplantation. However, the follow-up of transplanted patients showed that gut tissue changes do not revert and fatal complications, such as massive gastrointestinal bleeding, can occur. The purpose of this study was to clarify whether the reintroduction of TP after transplant can recover mtDNA copy number in a normal range. Using laser capture microdissection and droplet-digital-PCR, we assessed the mtDNA copy number in each layer of full-thickness ileal samples of a naive MNGIE cohort vs. controls and in a patient pre- and post-TP replacement. The treatment led to a significant recovery of gut tissue mtDNA amount, thus showing its efficacy. Our results indicate that a timely TP replacement is needed to maximize therapeutic success before irreversible degenerative tissue changes occur in MNGIE.
Identifiants
pubmed: 35955927
pii: ijms23158792
doi: 10.3390/ijms23158792
pmc: PMC9369323
pii:
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente 2021
Organisme : Ministry of Education, Universities and Research
ID : Personalized medicine
Organisme : University of Ferrara
ID : FAR
Organisme : University of Ferrara
ID : FIR
Références
Brain. 2015 Oct;138(Pt 10):2847-58
pubmed: 26264513
J Neurol. 2012 Sep;259(9):1985-7
pubmed: 22532170
J Clin Invest. 2003 Jun;111(12):1913-21
pubmed: 12813027
AJNR Am J Neuroradiol. 2018 Mar;39(3):427-434
pubmed: 29348134
Methods Mol Biol. 2011;755:223-32
pubmed: 21761307
J Inherit Metab Dis. 2021 Mar;44(2):376-387
pubmed: 32898308
J Neurol. 2020 Dec;267(12):3702-3710
pubmed: 32683607
Mol Genet Metab. 2020 May;130(1):58-64
pubmed: 32173240
Am J Pathol. 2008 Oct;173(4):1120-8
pubmed: 18787099
Brain. 2018 Jan 1;141(1):e3
pubmed: 29228108
Am J Physiol Gastrointest Liver Physiol. 2021 May 1;320(5):G768-G779
pubmed: 33655764
Gastroenterology. 2006 Mar;130(3):893-901
pubmed: 16530527
PLoS Genet. 2011 Mar;7(3):e1002035
pubmed: 21483760
Mol Cell. 2004 Apr 9;14(1):1-15
pubmed: 15068799
Pediatr Blood Cancer. 2021 May;68(5):e28926
pubmed: 33533561
Ann Neurol. 2016 Sep;80(3):448-55
pubmed: 27421916
Life (Basel). 2020 Aug 26;10(9):
pubmed: 32858900
Intern Med. 2006;45(19):1103
pubmed: 17077575
Neurotherapeutics. 2013 Apr;10(2):186-98
pubmed: 23385875
J Neurol. 2012 Dec;259(12):2699-706
pubmed: 22711161
Antivir Ther. 2003 Aug;8(4):315-21
pubmed: 14518701
Mol Genet Metab Rep. 2021 Dec 03;30:100829
pubmed: 34926160
Hum Mol Genet. 2004 Jan 1;13(1):91-101
pubmed: 14613972
FEBS Lett. 2021 Apr;595(8):976-1002
pubmed: 33314045